P-390 The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study
Kane Foster(London Cancer), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Evie Fitzsimons, James D. Cavenagh(National Health Service), Benny Chain(University College Lahore), Lydia Lee(CRUK Lung Cancer Centre of Excellence), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Suzanne Byrne(Brigham and Women's Hospital), William W. Wilson(Dakota State University), Karthik Ramasamy(Oxford University Hospitals NHS Trust), M.D. Chapman, Rakesh Popat(University College London Hospitals NHS Foundation Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Fuad Fananapazir(MRC Clinical Trials Unit at UCL), Sumaiya Kamora(Cancer Research UK), Elizabeth Philips, Selina J Chavda(University College London), Krupali Parikh, Reuben Benjamin(King's College London), Charlotte Tyson(Queen Mary University of London), Daria Galas‐Filipowicz(CRUK Lung Cancer Centre of Excellence)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605